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Abstract
Neural progenitor cells (NPs) have shown several 
promising benefits for the treatment of neurological 
disorders. To evaluate the therapeutic potential of hu-
man neural progenitor cells (hNPs) in amyotrophic lat-
eral sclerosis (ALS), we transplanted hNPs or growth 
factor (GF)-expressing hNPs into the central nervous 
system (CNS) of mutant Cu/Zn superoxide dismutase 
(SOD1G93A) transgenic mice. The hNPs were en-
gineered to express brain-derived neurotrophic factor 
(BDNF), insulin-like growth factor-1 (IGF-1), VEGF, 
neurotrophin-3 (NT-3), or glial cell-derived neuro-
trophic factor (GDNF), respectively, by adenoviral vec-
tor and GDNF by lentiviral vector before transplan-
tation. Donor-derived cells engrafted and migrated in-
to the spinal cord or brain of ALS mice and differ-
entiated into neurons, oligodendrocytes, or glutamate 
transporter-1 (GLT1)-expressing astrocytes while 
some cells retained immature markers. Transplanta-
tion of GDNF- or IGF-1-expressing hNPs attenuated the 
loss of motor neurons and induced trophic changes in 
motor neurons of the spinal cord. However, improve-
ment in motor performance and extension of lifespan 
were not observed in all hNP transplantation groups 
compared to vehicle-injected controls. Moreover, the 
lifespan of GDNF-expressing hNP recipient mice by 
lentiviral vector was shortened compared to controls, 
which was largely due to the decreased survival times 
of female animals. These results imply that although 
implanted hNPs differentiate into GLT1-expressing as-
trocytes and secrete GFs, which maintain dying motor 
neurons, inadequate trophic support could be harmful 
and there is sexual dimorphism in response to GDNF 
delivery in ALS mice. Therefore, additional therapeutic 
approaches may be required for full functional re-
covery. 
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Introduction
Amyotrophic lateral sclerosis (ALS) is a late-onset 
neurodegenerative disease characterized by progre-
ssive and lethal motor neuronal death. The di-
sease's hallmark is a selective degeneration and 
loss of motor neurons in the brain and spinal cord. 
Most cases (90%) are sporadic and about 10% are 
inherited (familial ALS). Mutations in the Cu/Zn 
superoxide dismutase (SOD1) gene are the most 
common form of inherited ALS, accounting for 
∼20% of all familial types. This has led to the 
generation of transgenic mice and rats carrying 
SOD1G93A that have many characteristics of human 
ALS pathology, and these are currently the most 
widely used models of disease (Lepore and Mara-
gakis, 2007). Although several hypotheses have 
been proposed to explain mutant SOD1-mediated 
pathogenesis, the exact mechanism responsible for 
motor neuron degeneration remains unknown (Bruijn 
et al., 2004; Boillee et al., 2006; Pasinelli and 
Brown, 2006). However, recent studies in the 
mutant SOD1 mouse suggest that the disease is 
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Figure 1. In vitro immunocytochemistry of viral vector-infected hNPs. Growth factors are secreted by GFP-expressing hNPs. GFP-positive cells (green) 
are identified by various GF markers that are visualized by Texas red. Double labeling, seen as yellow/orange fluorescence, is observed by dual bypass 
filter microscopy. (A-C) hNPs-AdBDNF. (D-F) hNPs-AdNT-3. (G-I) hNPs-AdGDNF. (J-L) hNPs-AdIGF-1. (M-O) hNPs-AdVEGF. (P-R) hNPs-LtGDNF. Scale 
bar: 10 μm. 
non-cell autonomous to motor neurons (Clement et 
al., 2003), cells neighboring motor neurons such as 
mutant astrocytes and microglia strongly accele-
rate disease progression (Beers et al., 2006; Boillee 
et al., 2006; Yamanaka et al., 2008b), and mutant 
SOD1 in cell types other than motor neurons and 
oligodendrocytes contribute to the initiation of motor 
neuron degeneration (Yamanaka et al., 2008b). 
Among several possibilities, mutant astrocytes could 
lead to glutamate-dependent excitotoxicity due to 
loss of glutamate transporter-1 (GLT1) [excitatory 
amino acid transporter-2 (EAAT2) in humans] 
(Howland et al., 2002), enhance inflammatory 
response from microglia (Yamanaka et al., 2008b), 
be unable to regulate glutamate receptor subunit 2 
expression in motor neurons (Van Damme et al., 
2007), or release 1 or more unknown toxic factors 
that accelerate the death of embryonic stem 
cell-derived motor neurons (Di Giorgio et al., 2007; 
Nagai et al., 2007).
    Many clinical trials and studies have been under-
taken to find effective therapies for ALS, but proven 
methods still do not exist. Recently, some trials of 
effective growth factor (GF) delivery have been 
reported in ALS model based on the assumption 
that the provision of GF, which could be trophic for 
motor neurons, would be of benefit in motor neuron 
disorders. Injection of adeno-associated virus (AAV) 
encoding insulin-like growth factor-1 (IGF-1) gene 
into muscle slowed disease progression in ALS 
mice (Kaspar et al., 2003), and delivery of a 
lentivirus encoding VEGF extended survival of ALS 
mice (Azzouz et al., 2004). However, current viral 
vectors cannot alter dosage or discontinue therapy 
and have significant limitations for reaching wide-
spread areas of the CNS. In addition, retrograde 
transport may be affected early in the disease 
(Williamson et al., 1999), and larger animals such 
as monkeys may be less efficient at taking back 
the protein to the spinal cord, thus limiting this 
approach in patients. Another approach for GF 
delivery is the direct infusion of trophic molecules 
into the spinal cord or brain, which yields wides-
pread distribution throughout the CNS. Continuous 
intracerebroventricular (ICV) infusion of VEGF or 
IGF-1 extended survival time in ALS mice, and a 
phase I clinical trial using the same strategy showed 
a modest benefit in patients without adverse effects 
(Nagano et al., 2005a, b; Storkebaum et al., 2005). 
However, direct delivery of GF in vivo has been 
hindered by limited bioavailability, inability to 
penetrate gray matter, and a relatively short 
half-life.
    Neural progenitor cells (NPs) possess a range of 
therapeutic properties for neural repair: functional 
neuronal or glial replacement, delivery of thera-
peutic gene products synthesized by stem cells, 
mitigation of toxic or inflammatory components of 
the neural environment, and replacement of multiple 
neural elements that define a given CNS region 
(Snyder et al., 1995; Flax et al., 1998; Imitola et al., 
2004; Park et al., 2002, 2006a, b; Lee et al., 2007). 
The human neural progenitor cells (hNPs) can be 
expanded in long-term cultures, and differentiate 
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Figure 2. Engraftment and distribu-
tion of hNPs in vivo following trans-
plantation. (A) GFP-expressing do-
nor-derived cells (green) show mi-
gration from the fourth ventricle 
(asterisk) to the adjacent brain stem 
when the mice were analyzed 2 
weeks after transplantation. Arrows 
indicate migrating cells into the pa-
renchyma of the brain stem. (B) 
GFP-positive cells engraft within the 
medulla (an arrow). (C-E) Some do-
nor-derived cells show engraftment 
in the white matter of the thoracic 
spine of mice (arrows). (D) GFP-po-
sitive cells were identified by human 
cell-specific marker hHSP27 visua-
lized by Texas red. (E) Double label-
ing, seen as yellow/orange fluores-
cence, is observed by dual bypass 
filter microscopy. (F-H) Human spe-
cific GFAP-positive cells (arrow heads, 
red) appear to have migrated from 
the white matter to the gray matter 
of the thoracic spine of mice when 
analyzed at 4 weeks following trans-
plantation. Asterisk markers indicate 
the subarachnoid space of the spi-
nal cord. Scale bar: A, 40 μm; C, 10 
μm; F, 20 μm.
into neural cell types and integrate into host neural 
circuitry after transplantation into the developing 
and adult rodent CNS (Svendsen et al., 1997; Flax 
et al., 1998; Imitola et al., 2004; Kim et al., 2006; 
Lee et al., 2007). The hNPs can also be engi-
neered to release glial cell-derived neurotrophic 
factor (GDNF) and survive transplantation into the 
lumbar spinal cord of the SOD1G93A rat. These cells 
continue to release GDNF within the degenerative 
environment of the spinal cord and show a 
protective effect on motor neuron cell death (Klein 
et al., 2005; Suzuki et al., 2007a). However, this 
was not through the differentiation of donor-derived 
cells into GLT1-expressing astrocytes around the 
surviving motor neurons, and GDNF-expressing 
hNP grafts did not extend survival times in ALS 
rats. Therefore, in the present study, simultaneous 
combined strategies of hNP transplantation that 
could not only replace non-neuronal cells but also 
effectively deliver GF to the CNS were performed 
in ALS mice. Both replacement of GLT1-expre-
ssing astrocytes and delivery of GF such as IGF-1 
or GDNF maintain dying motor neurons. However, 
improvement in motor performance and extension of 
lifespan were not observed. These results indicate 
possible hNP treatment strategies to maintain dying 
motor neurons for ALS, however, other therapeutic 
approaches are required for full functional recovery. 
Results
In vitro characterization of viruses and
virus-infected hNPs
The titer of each adenovirus was about 2-6 × 1012 
pfu/ml. To demonstrate and optimize adenoviral 
infection on hNPs, we infected hNPs with AdGF at 
different MOI ranges between 0 and 250 pfu per 
cell. When cells were infected with AdGF at 80 
MOI, nearly 100% of hNPs appeared to be 
GFP-positive and healthy. The amount of secreted 
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Figure 3. Differentiation patterns of 
hNPs in vivo following transplan-
tation. (A-C) The hNuc-positive do-
nor-derived cells visualized by Texas 
red (arrows in A and C) are co-la-
beled with TUJ1, a neuronal marker 
that is identified by fluorescein 
(arrows in B and C, green) in the 
cervical and thoracic spine of mice. 
(G-I) A major portion of hNuc-pos-
itive cells express hNestin (arrows 
in G and I, red), an immature cell 
marker in the thoracic spine. (D-F) 
When hNPs-LtGDNF are injected in-
to mice, a small number of GFP- 
positive donor-derived cells (arrows 
in D and F) express TUJ1 (arrows in 
E and F, red) in the spinal cord, 
(J-L), however, a major portion of 
GFP-positive cells express hGFAP 
(arrows in K and L, red) in the brain 
stem and spinal cord of mice. (M-O) 
Some donor-derived hGFAP-pos-
itive cells (arrows in M and O, red) 
express EAAT2 (arrows in N and O, 
green) in the cervical and thoracic 
spine of mice. Scale bar: A, 10 μm. 
brain-derived neurotrophic factor (BDNF), GDNF, 
and IGF-1 from 1 × 106 cells for 48 h was 75.67, 
82.13, and 84.68 ng, respectively. In contrast, 
AdVEGF was used at 8 MOI because transplan-
tation of hNPs expressing high amounts of VEGF 
induced death in some experimental mice. The 
amount of secreted VEGF was 9.04 ng from 1 ×
106 cells for 48 h. The titer of lentivirus was 1.08 ×
105 TU/μl, and the cells were infected at 3 MOI. 
According to ELISA, hNPs-LtGDNF secreted 31.89 
ng of GDNF from 1 × 106 cells during 48 h under 
proliferative conditions. 
    We performed immunocytochemistry to charac-
terize hNPs-AdGF and hNPs-LtGDNF under diffe-
rentiation conditions. Transduction of the viral vector 
was confirmed by GFP and GF expression (Figure 
1). The majority of viral vector-infected hNPs 
(∼90%) expressed immature cell marker nestin, 
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Figure 4. Motor neurons are pro-
tected by EAAT2- and GDNF-ex-
pressing donor-derived astrocytes 
following hNPs-LtGDNF transplanta-
tion in the spinal cord of ALS mice. 
(A-F) The hGFAP-positive donor-de-
rived astrocytes visualized by Texas 
red (arrows in A, C, D, and F) are 
co-labeled with EAAT2 and GDNF, 
which are identified by fluorescein 
(arrows in B, C, E, and F, green), in 
the thoracic spine at 4 weeks 
post-grafting. (G-I) The hGFAP-pos-
itive donor-derived astrocytes (arrow 
heads in G and I, red) located ad-
jacent to NF-positive host motor 
neurons and their cell bodies (arrows 
in H and I, green) in the gray matter 
of the thoracic spine. (H-J) In ve-
hicle-injected mice, the number NF- 
positive motor neurons is signifi-
cantly reduced and the size of the 
motor neuron cell body appears to 
be smaller (an arrow in J, green) 
compared to hNPs-LtGDNF-injected 
mice (arrows in H and I, green). 
Scale bar: A, 5 μm; G, 10 μm. 
and many of them expressed more than 1 of the 
cell type-specific proteins studied, which suggests 
that cells are double-labeled with glial and neuro-
nal markers are multipotent progenitors (Kim et al., 
2006) (data not shown). For example, according to 
types of infected viruses and secreting GF, about 
30-90% of cells expressed GFAP, a protein that is 
expressed by astrocytes and neural stem cell/pro-
genitor cells, and about 25-45% of cells expressed 
TUJ1, a neuronal marker. However, only a low 
percentage (∼1%) of cells expressed O4, an 
immature oligodendrocyte marker (data not shown). 
These results indicate that a major portion of 
virus-infected GF-secreting hNPs still remain imma-
ture state under differentiation conditions in vitro.  
Engraftment and distribution of hNPs in vivo 
following transplantation
The animals were sacrificed at 2 or 4 weeks 
following transplantation and the end point of the 
disease. In all experimental groups, hNPs and 
GF-expressing hNPs showed migration and engraft-
ment throughout the spinal cord or brain when 
implanted via the cisterna magna or cerebral 
lateral ventricles, respectively (Figure 2-5). In vivo 
distribution of the donor-derived cells was identified 
by the expression of GFP, human cell-specific 
markers (hHSP27, hNuc and hGFAP), or BrdU. 
GFP-expressing donor-derived cells in vivo indicate 
that they also express GF simultaneously. Donor- 
derived cells migrated from the injection site to the 
adjacent brain stem and whole spinal cord when 
injected into the cisterna magna. GFP-expressing 
donor derived cells appeared to be migrating 
toward the adjacent brain stem from the fourth 
ventricle and engrafted within the medulla when 
mice were analyzed 2 weeks after transplantation 
(Figure 2A and B). Some donor-derived cells might 
migrate through the subarachnoid space and 
become engrafted into the white matter of the 
cervical or thoracic spines (Figure 2C-E). In a few 
cases, some engrafted cells could be found in the 
area of the lumbar spine of ALS mice. Moreover, 
human-specific GFAP-positive cells showed migra-
tion from white matter to gray matter of the cervical 
or thoracic spine of mice 4 weeks following trans-
plantation (Figure 2F-H).
Differentiation patterns of hNPs in vivo following 
transplantation
To investigate the patterns of differentiation of 
donor-derived cells, the brain stem and whole spinal 
cord of ALS mice were analyzed by immunohis-
tochemistry at 4 weeks following transplantation. 
About 20% of implanted hNPs could be found to 
differentiate into TUJ1-positive neurons in the 
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Figure 5. Transplantation of IGF-1- 
expressing hNPs attenuates motor 
neuron loss and induces trophic ef-
fects in motor neurons of ALS mice. 
(A-F) BrdU-positive donor-derived 
cells (arrow heads in A, C, D, and F, 
green) are shown to be engrafted 
juxtapositionally to NeuN- or TUJ1- 
postive host motor neurons (arrows 
in B, C, E, and F, red) in the gray 
matter of the thoracic spine of ALS 
mice. Host motor neurons appear to 
have larger cell bodies, longer neu-
ronal processes, and enhanced 
neurites branching and elongation. 
(G and H) While Chat-positive host 
motor neurons show larger cell bod-
ies and elongated and branching 
neuronal processes in hNPs-AdIGF- 
1-transplanted mice (arrows in G, 
red), the number of large Chat-pos-
itive host motor neurons is de-
creased and the morphology of cell 
bodies appears to have shrunken 
(arrows in H, red) in vehicle-injected 
controls. Scale bar: E, 40 μm; G, 20 
μm.
cervical or thoracic spine of mice (n = 10) (20.4 ±
1.3%, mean ±SEM) (Figure 3A-C), however, a major 
portion of the engrafted cells remained hNestin-ex-
pressing immature cells in the spinal cord (n = 10) 
(50.6 ± 1.5%) (Figure 3G-I). Some donor-derived 
cells also differentiated into GFAP-expressing astro-
cytes (n = 10) (28.5 ± 1.7%) but there was hardly 
any CNPase-positive oligodendrocytes (less than 
1%) (data not shown). When hNPs-LtGDNF was 
injected into the mice, only ∼1% of donor-derived 
cells differentiated into TUJ1-positive neurons 
(Figure 3D-F), however, more than 50% of im-
planted cells expressed hGFAP in the brain stem 
and spinal cord of the mice (n = 8) (53.5 ± 2.1%) 
(Figure 3J-L). In addition, ∼30% and ∼5% of 
GFAP-expressing donor-derived astrocytes expre-
ssed EAAT2 and EAAT1, respectively, in the cervical 
or thoracic spine of the mice (n = 5) (30.8 ± 1.1% 
and 4.7 ± 0.5%) (Figure 3M-O). These results 
suggest that hNPs-LtGDNF-derived astrocytes could 
protect host motor neurons by reducing glutamate 
mediated excitotoxicity. 
Survival and trophic effects of GF-expressing hNP 
transplantation on motor neurons of the spinal cord
Among all transplantation groups, GDNF- and IGF- 
1-expressing hNP implantation showed survival 
and trophic effects on motor neurons of the spinal 
cord of mice. When mice were analyzed 4 weeks 
following hNPs-LtGDNF transplantation, some 
donor-derived astrocytes could be found to express 
EAAT2 and GDNF in the cervical or thoracic spine 
(Figure 4A-F). To investigate whether GDNF- 
and/or EAAT2-expressing donor-derived astrocytes 
could attenuate motor neuron loss and induce 
trophic effects on motor neurons, we counted the 
number of choline acetyltransferase (Chat), NF, or 
NeuN-positive cells and observed the size of their 
cell bodies in the thoracic spine of both the 
hNPs-LtGDNF and vehicle-injected groups. By 4 
weeks post grafting (∼103-day-old animals), there 
was a significant (∼23%) reduction in the number 
of motor neurons in the vehicle-injected group 
(Figure 4J) compared to the hNPs-LtGDNF-injected 
group (Figure. 4G-I). The average number of motor 
neurons per longitudinal section of the thoracic 
spine in the vehicle and hNPs-LtGDNF injected 
groups (n = 5) was 423 ±32 and 550 ±25, respec-
tively. The hGFAP-positive donor-derived cells were 
located adjacent to host motor neurons and their 
cell bodies in the gray matter of thoracic spine, and 
the size of motor neuron cell bodies appeared to 
be bigger than that of the control group (Figure 
4G-J). In case of hNPs-AdIGF-1 transplantation, 
BrdU-positive donor-derived cells were shown to 
be located juxtapositionally to the host motor 
neurons in the thoracic spine of ALS mice, and the 
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Figure 6. Transplantation of hNPs 
and GF-expressing hNPs do not im-
prove motor performance in ALS 
mice. (A and B) Although hNPs- 
AdGDNF-implanted mice show a 
significant short-term increase in fall 
down time in the rota-rod and wire 
maneuver tests at 2 or 3 weeks fol-
lowing transplantation, there is no 
significant difference overall in fall 
down time among all hNPs and 
hNPs-AdGF transplantation groups 
and vehicle-injected controls. (C) 
hNPs-LtGDNF-implanted mice also 
show a significant short-term in-
crease in fall down time in the ro-
ta-rod test compared to the control 
group at 3 and 4 weeks following 
transplantation, however, after then, 
fall down time becomes shorter than 
the control group. (D and E) Follo-
wing transplantation, the early sig-
nificant increase in fall down time in 
the rota-rod test is due to improved 
performance in male mice of the 
hNPs-LtGDNF-transplanted group 
compared to male mice of the con-
trol group whereas the late signi-
ficant decrease in fall down time in 
the hNPs-LtGDNF-transplanted group 
is largely due to the worsened per-
formance in female mice compared 
to female mice of the control group. 
(F) There is no difference in fall down 
time in the wire maneuver test be-
tween both groups. Values are 
mean ± SEM, *P ＜ 0.05.
host motor neurons appeared to have larger cell 
bodies, longer neuronal processes, and enhanced 
neurites branching and elongation compared to 
vehicle-injected controls (Figure 5). 
Effects of hNPs and GF-expressing hNP 
transplantation on motor performance
We performed the wire maneuver and rota-rod 
tests to evaluate the effects of hNPs and GF-ex-
pressing hNP transplantation on motor function in 
ALS mice. We also observed changes in body 
weight in all transplantation groups and vehicle-in-
jected controls from before transplantation up to 
death (data not shown). Overall, there was no 
significant difference in motor performance and 
body weight transition among the hNPs and 
hNPs-AdGF transplantation groups and vehicle-in-
jected controls although hNPs-AdGDNF implanted 
mice showed short-term transient improvement in 
motor performance during the early period following 
implantation (Figure 6A and B). The number of 
mice examined in the vehicle, hNPs, hNPs-AdBDNF, 
AdIGF-1, hNPs-AdVEGF, and hNPs-AdGDNF trans-
planted groups was 128, 16, 18, 22, 29, and 46, 
respectively. In the hNPs-LtGDNF transplanted group 
(n = 40), motor performance in the rota-rod test 
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Figure 7. Survival curves. (A) Survi-
val curves of hNPs- and hNPs- 
AdGF-transplanted mice and ve-
hicle-injected mice. There are no dif-
ferences in survival duration among 
all hNPs- and hNPs-AdGF-trans-
planted groups and vehicle-injected 
group. (B) Survival curves of hNPs- 
LtGDNF-transplanted and control 
mice. The hNPs-LtGDNF transplan-
tation significantly decreases surviv-
al times (P ＜ 0.01). (C) Survival 
curves of hNPs-LtGDNF-transplanted 
male and control male mice. There 
is no difference between both groups. 
(D) Survival curves of hNPs- 
LtGDNF-transplanted female and 
control female mice. In female mice, 
cell transplantation significantly de-
creases survival times (P ＜ 0.01). 
was better than in the vehicle-injected controls (n =
37) at 3 and 4 weeks following transplantation, 
however, after then, performance became worse 
compared to the control group (Figure 6C). When 
the results of the rota-rod test were analyzed by 
gender of the mice, male mice in the hNPs-LtGDNF 
transplanted group had better performance during 
the early period following transplantation than male 
mice in the control group whereas the late dete-
rioration in motor performance in the hNPs-LtGDNF 
transplanted group was largely due to worsened 
performance in female mice (Figure 6D and E). 
However, there was no difference on the wire 
maneuver test between both groups (Figure 6F). 
Effects of hNPs and GF-expressing hNP 
transplantation on the survival of ALS mice
To test the role of transplantation of hNPs and 
GF-expressing hNPs on disease outcome, we ob-
served the lifespan in all transplantation groups and 
vehicle-injected controls. There were no statistical 
differences among hNPs (n = 16) and hNPs-AdGF- 
transplanted mice (n = 115) and vehicle-injected 
mice (n = 124) in survival duration (hNPs, 137.1 ±
4.1 d; hNPs-AdBDNF, 139.2 ± 4.1 d, n = 18; hNPs- 
AdIGF-1, 134.5 ± 2.9 d, n = 22; hNPs-AdVEGF, 
133.5 ± 1.6 d, n = 29; hNPs-AdGDNF, 135.8 ± 1.9 
d, n = 46; vehicle, 133.8 ± 3.9 d) (Figure 7A). In 
contrast, hNPs-LtGDNF suspension transplanta-
tion significantly decreased overall survival. The 
average survival times in the vehicle and hNPs- 
LtGDNF groups were 143.3 ± 2.9 d (n = 21) and 
132.8 ± 2.0 d (n = 23) when injected into the 
cisterna magna and 142.5 ± 2.5 d (n = 16) and 
135.5 ± 2.2 d (n = 17) when injected into both the 
cisterna magna and cerebral lateral ventricle, re-
spectively (Figure 7B). Both data show statistically 
significant differences between the hNPs-LtGDNF 
and control groups (P＜0.05).
    In order to evaluate gender difference on survival 
duration, we separately analyzed survival times of 
male and female mice in both the hNPs-LtGDNF 
and control groups. In male mice, the mean survival 
times of the vehicle (n = 19) and hNPs-LtGDNF 
groups (n = 24) were 136.0 ± 2.2 d and 130.8 ± 
1.8 d, respectively, when injected into the cisterna 
magna or both the cisterna magna and cerebral 
lateral ventricle. There was no statistically difference 
between both groups (Figure 7C). However, in 
female mice, the mean survival times of the vehicle 
(n = 18) and hNPs-LtGDNF groups (n = 16) were 
150.3 ± 2.2 d and 138.6 ± 2.2 d, respectively, and 
there was a significantly difference between both 
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groups (P ＜ 0.05) (Figure 7D). Therefore, the ne-
gative effect of hNPs-LtGDNF transplantation into 
ALS mice on survival time was mainly due to the 
shortened survival period in female mice.   
Discussion
Transplantation of neural stem/progenitor cells has 
shown a range of therapeutic potential for neuro-
logical disorders because engrafted cells could 
replace lost or dysfunctional neurons and glias, 
deliver various growth factors or other therapeutic 
gene products that expressed intrinsically or engi-
neered ex vivo to be overexpressed by the 
stem/progenitor cells, mitigate toxic or inflamma-
tory components of the neural environment, replace 
multiple neural elements that define a given CNS 
region, and integrate seamlessly into host neural 
circuitry. 
    Previous studies of motor neuron disease models 
showed that transplantation of embryonic or neural 
stem cell-derived neural precursors replaced motor 
neurons, and established some connection in part 
with peripheral targets in a functional manner (Wu 
et al., 2002; Kerr et al., 2003; Harper et al., 2004; 
Deshpande et al., 2006). However, this strategy 
still has many limitations associated with appro-
priate motor neuron differentiation, axonal extension 
into the peripheral nervous system, formation of 
functional neuromuscular junction, and establish-
ment of a functional neural network with the host 
nervous system. 
    Other cell transplantation approaches that did 
not replace injured motor neurons, including those 
with enhanced growth factor expression, also sho-
wed some improvement in ALS models (Aebischer 
et al., 1996; Garbuzova-Davis et al., 2002, 2003; 
Corti et al., 2004, 2007; Llado et al., 2004; Xu et 
al., 2006; Yan et al., 2006; Martin and Liu, 2007). 
Moreover, administration of growth factors was 
reported to have some beneficial roles on disease 
outcome in ALS rodent models (Federici and 
Boulis, 2006). Thus, stem/progenitor cell-based ex 
vivo gene therapy, employing cells genetically 
engineered to express growth factors, could provide 
not only appropriate missing neurons or glias but 
also simultaneously trophic factors for motor neu-
rons in ALS models after transplantation. However, 
when GDNF-expressing human neural progenitor 
cells were directly transplanted into the lumbar 
spinal cord, there were no benefits in motor perfor-
mance and animal survival although they provided 
limited neuroprotection (Klein et al., 2005; Suzuki 
et al., 2007a). 
    The diffuse distribution of grafted cells throughout 
the CNS via direct transplantation of stem/pro-
genitor cells into cerebrospinal fluid (CSF) may be 
a potential alternative to intraparenchymal injection 
because ALS is characterized by relatively selective 
degeneration of motor neurons in the brain and 
spinal cord. Previous studies have demonstrated 
that neural stem/progenitor cells can be delivered 
to the brain and spinal cord via intraventricular and 
intrathecal injection because of their responsive-
ness to signals derived from the injured and 
degenerating CNS (Flax et al., 1998; Park et al., 
2002, 2006a, b; Kerr et al., 2003; Lepore and 
Maragakis, 2007). Therefore, in this study, we 
initially hypothesized that the intrathecal injection 
of hNPs and GF-expressing hNPs by adenoviral 
vector through the cistern magna would show 
decreased motor neuron death and increase animal 
survival times. However, these cells overall do not 
improve motor behavior and animal survival although 
some donor-derived cells distribute diffusely in the 
brain stem and spinal cord and differentiate into 
neurons and astrocytes but largely retain the 
immature cell marker nestin and show limited 
protective effects on motor neurons. The only 
positive result is that GDNF-expressing hNP-im-
planted mice show short-term improvement in 
motor performance. As our next experiment, we 
transplanted GDNF-expressing hNPs by lentiviral 
vector because the expression of adenovirally 
delivered GDNF might be transient and insufficient, 
and hNPs-LtGDNF appear to have gained more 
glial cells-specific differentiation capacity, especially 
astrocytes, according to in vitro and in vivo diffe-
rentiation experiments. However, as a result, motor 
performance and extension of lifespan were not 
improved but instead worsened in female mice. 
    As described earlier, intrathecal and/or ventricular 
injection of cells have several advantages, such as 
wide distribution of administered cells, easy appli-
cation, and noninvasive methods. In this study, 
some transplanted hNPs-LtGDNF could survive and 
migrate into host tissues, differentiate into neurons 
and glias, including astrocytes expressing EAAT2 
and GDNF, and exert neuroprotective influences 
on neighboring host motor neurons. However, many 
cells remained in the ventricular region and CSF 
tract of the spinal cord until 4 weeks after trans-
plantation, and their engraftments and integrations 
seemed to be very limited. Because of the low 
nutrient level of CSF, the survival rate of trans-
planted cells might be low (Habisch et al., 2007). 
Furthermore, disruption of the blood-brain barrier 
and blood-spinal cord barrier in SOD1G93A trans-
genic mice was reported (Garbuzova-Davis et al., 
2007). Thus, use of high doses of immune suppre-
ssants or combined immune suppressants would 
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be required to increase the viability of donor-derived 
cells affected by immune rejection and chances for 
functional recovery. 
    In ALS mice models, axonopathy is known to 
induce loss of neural connection to the muscle at 
the neuromuscular junction long before motor 
neuron degeneration and initiation of symptoms 
(Fischer, et al., 2004; Pun et al., 2006). Transplan-
tation of GDNF-expressing human neural precursor 
cells in ALS rat models induced survival of motor 
neurons in the spinal cord, but did not reduce the 
number of denervated muscle end plates (Suzuki 
et al., 2007). In addition, a recent study showed 
that when motor neurons were transplanted, axonal 
outgrowth and attachment to the muscle could be 
achieved by using GDNF-secreting cells implanted 
into the sciatic nerve (Deshpande et al., 2006). 
These findings suggest that combinatorial approa-
ches of the protection of motor neuron cell bodies 
and nerve terminals in the muscle may lead to 
potential improvements in limb function and survival 
of ALS mice. 
    In this study, the effects of transplantation of 
hNPs-LtGDNF in motor performance and survival 
of ALS mice were negative. The main reason was 
worsened motor performance and survival in female 
mice. Late disease onset and slow progression of 
female SOD1 mice has been reported (Suzuki et 
al., 2007b), and the protective role of estrogen in 
female mice appear to influence disease progre-
ssion (Choi et al., 2008). Interestingly, estrogen 
stimulates the expression of GDNF in the deve-
loping hypothalamus (Ivanova et al., 2002). There-
fore, excessive expression of GDNF in the CNS due 
to hNPs-LtGDNF transplantation could be one of the 
reasons for the negative effects on motor perfor-
mance and survival of female SOD1 mice. We also 
observed some irritable behaviors, such as jumping, 
squeaking, and turning, in female mice after cells 
were injected through both the cisterna magna and 
intracerebral ventricle. The delivery of growth factors 
for a long period in the CNS could be harmful. In 
patients with Parkinson’s disease, side effects of 
centrally delivered GDNF have been reported 
(Kordower et al., 1999; Nutt et al., 2003). As we 
observed in mice transplanted with NPs-AdVEGF, the 
delivery of low-dose VEGF would be better than a 
high dose in Parkinson’s models (Yasuhara et al., 
2005). Therefore, modulation of expression level of 
growth factors in vivo seems to be very important. 
However, the precise mechanisms of the negative 
effects of hNPs-LtGDNF transplantation of female 
SOD1 mice in this study need to be clarified. 
    In chimeric mutant SOD1 mice, the aberrant 
function of non-neuronal cells (microglia and astro-
cytes) appears to contribute to disease progre-
ssion (Clement et al., 2003; Boillee et al., 2006; 
Yamanaka, et al., 2008a). Chimeric mutant SOD1 
animals suggest that increasing the proportion of 
healthy wild-type non-neuronal cells is related to 
the prolongation of animal survival times. Selective 
reduction of mutant SOD1 from astrocytes results 
in prolongation of disease duration (Yamanaka, et 
al., 2008a). Astrocytes in ALS patients and animal 
models have been revealed to have functional 
abnormalities in glutamate transport, specifically 
GLT1 (EAAT2) (Rothstein et al., 1995; Howland et 
al., 2002). Loss of this astroglial protein is known to 
cause excitotoxic motor neuron degeneration (Ro-
thstein et al., 1996). Furthermore, ALS astrocytes 
alter the expression of dendritic glutamate (AMPA) 
receptors in motor neurons, also making them more 
susceptible to excitotoxicity (Lepore et al., 2008). 
More recent studies also suggest that human mutant 
SOD1 carrying astrocytes release several toxic 
factors, including the activation of NOX2 to produce 
oxygen radicals, which induce embryonic stem 
cell-derived motor neuron degeneration (Di Giorgio 
et al., 2007, 2008; Nagai et al., 2007; Marchetto, et 
al., 2008). Thus, these results indicate that any 
approach to replace altered astroglial function may 
be of therapeutic benefit. A recent study showed that 
focal transplantation of glial-restricted precursors into 
the cervical spine of ALS models efficiently diffe-
rentiate into GLT1-expressing normal astrocytes, 
attenuate motor neuron loss, slow declines in motor 
functions, and extend survival and disease duration 
of animals (Lepore et al., 2008). In the present study, 
some transplanted hNPs-LtGDNF also differentiated 
into EAAT2- and/or EAAT1-expressing astrocytes in 
the brain stem and spinal cord of mice, and 
appeared to play a role in attenuating motor neuron 
death. However, compared to the study mentioned 
above, intrathecal transplantation of GDNF-expre-
ssing human neural progenitors in this study showed 
decreased engraftment and survival of donor-derived 
cells in the spinal cord, inaccurate targeting to key 
motor neuron pools that ultimately affect survival in 
ALS models, and inefficient differentiation into func-
tional mature astrocytes that reduce excitotoxic 
motor neuron death. 
Methods
Animals
We used SOD1 transgenic mice (Jackson Laboratories, 
Bar Harbor, ME) expressing the human SOD1G93A gene 
(G93A; Gly93 → Ala mutation) for the ALS model. The 
mutation has a dominant gain-of-function effect. Male 
transgenic mice were bred with background-matched 
B6C3/F1 wild-type females. The progeny were genotyped 
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by PCR at 4-5 weeks after birth as previously described 
(Gurney, 1994), and maintained as SOD1G93A hetero-
zygotes for subsequent studies. All transgenic ALS mice 
received the same care and housing and were evenly 
distributed to control and transplantation groups.
Cell culture
Human fetal tissue from cadavers at 13 weeks of gestation 
was obtained with full parental consent and approval of the 
research ethics committee of Yonsei University College of 
Medicine, Seoul, Korea. The methods of acquisition con-
formed to NIH and Korean government guidelines. The 
telencephalic brain tissue was dissected, dissociated in 
trypsin, and seeded into tissue culture-treated 100-mm 
plates (Corning) with serum-free growth medium. Mitogenic 
stimulation was achieved by adding fibroblast growth 
factor-2 (FGF2; R&D, Minneapolis, MI) and leukemia 
inhibitory factor (LIF; Sigma, St. Louis, MO). The concrete 
manners of the hNP culture as neurospheres are des-
cribed in a previously published paper (Kim et al., 2006).
Viral vector construction
We constructed recombinant adenoviral vectors bearing 
human BDNF, IGF-1, VEGF, NT-3, or GDNF under the 
control of the constitutive cytomegalovirus (CMV) pro-
moter, and placed these in tandem with a sequence of 
humanized version of the recombinant green fluorescent 
protein (hrGFP; Stratagene, La Jolla, CA) gene under the 
control of an internal ribosomal entry site (IRES) (Supple-
mental Data Figure S1A). Adenoviral vectors constructed 
in this fashion were designated as AdBDNF, AdIGF-1, 
AdVEGF, AdNT-3, AdGDNF, or AdGF as a whole, and 
produced in conformity with the AdEasy Adenoviral Vector 
System manual (Stratagene). Infectious recombinant viruses 
were purified by CsCl gradient centrifugation and titrated 
on 293 cells by Tissue Culture Infecting Dose 50 (TCID50; 
QBiogene). 
    We constructed a lentiviral vector carrying the GDNF 
gene, which was designated as LtGDNF. LtGDNF was 
produced by calcium-precipitate-transfection (transient trans-
fection) method using vectors that had been obtained from 
Trono lab (http://tronolab.epfl.ch/) in accordance with the 
method offered by the manufacturer. The backbone of 
transfer vector is pWPI (Supplemental Data Figure S1B). 
The packaging and envelope plasmids are psPAX2 and 
pMD2G, respectively. Enhanced green fluorescent protein 
(eGFP) is a reporter gene. The transfection was conducted 
to the 293FT cell line and produced viral vectors were 
concentrated by ultracentrifugation under the sucrose 
cushion. The viral titer was checked as transducing units 
(TU) by FACS analysis method offered by Trono lab.
Viral vector infection
For adenoviral vector transduction, hNPs were seeded 
onto cell culture dishes with serum-free growth medium 
containing FGF2, LIF, and heparin. One hour later, recom-
binant adenoviruses encoding BDNF, IGF-1, VEGF, NT-3, 
or GDNF were added to each well with a multiplicity of 
infection (MOI) of 80. The medium was replaced with fresh 
one the next day, and transplantation of cells into mice was 
conducted 3 days following viral infection. Conditioned 
media were collected from adenoviral infected-hNP cultures 
to determine the levels of secreted adenovirus-derived 
BDNF, IGF-1, VEGF, NT-3, or GDNF via ELISA as pre-
viously described (Woodhall et al., 2001).
    The transduction method of lentiviral vector encoding 
GDNF into hNPs was the same as for adenovirus. The titer 
of lentivirus was 3 MOI, and the level of GDNF secreted 
from hNPs was checked by PCR and ELISA. To confirm 
the safety of lentiviral infection, we had observed the 
survival, cellular morphology, and GFP and GDNF expre-
ssion patterns of lentivirus-infected hNPs for at least 10 
weeks prior to transplantation. In addition, neural cell types 
and morphologies of lentivirus-infected hNPs under proli-
feration and differentiation conditions were observed and 
identified by immunocytochemistry.
Transplantation
Adenovirus encoding GF or lentivirus encoding GDNF in-
fected hNPs (designated as hNPs-AdGF or hNPs-LtGDNF) 
were prelabeled by ex vivo exposure to bromodeoxyuridine 
(BrdU, 3 μM/L; Sigma) for 5 days before transplantation. 
After anesthesia with an intraperitoneal injection of keta-
mine (50 mg/kg) and xylazine (10 mg/kg), the mice were 
fixed on a Benchmark digital stereotaxic instrument 
(myNeuroLab.com, St. Louis, MO). Ten μl of hNPs, 
hNPs-AdGF, or hNPs-AdGDNF suspended in H-H buffer (1 
× Hanks' balanced salt solution, 10 mM HEPES, pH 7.4; 
GIBCO) were slowly injected into the cisterna magna of 
ALS mice using a 26-gauge needle about 75 days after 
birth. In some ALS mice, hNPs-LtGDNF suspension was 
injected not only into the cisterna magna but also the 
bilateral cerebral ventricles (4 μl into each cerebral ven-
tricle). The ventricular injection sites were 0.9 mm lateral 
and 0.1 mm anterior to the bregma and 2 mm deep from 
the dura. H-H buffer was injected into the littermate 
heterozygote mice in the control group. Cyclosporine was 
injected (10 mg/kg) intraperitoneally daily from the day 
before transplantation to the day of death or sacrifice in all 
hNP transplantation groups and vehicle-injected controls. 
Behavior tests
To evaluate impairment in motor function in ALS mice, we 
measured body weight and motor performance using a 
wire-maneuver and rota-rod (Columbus Instruments, 
Columbus, OH) test once a week from the week before 
hNP transplantation. The maximum time allowed to an 
animal was 180 s in the wire-maneuver test and 300 s in 
the rota-rod test. Survival analysis was also conducted 
along with the behavioral tests. Mouse mortality was 
determined by the day of death or inability to right itself 
within 30 s when the mouse was placed on its side. During 
the behavior test, we also evaluated whether hNP trans-
plantation could have an influence on the normal behavior 
of mice.
Immunochemistry
Using various cell type-specific markers to characterize the 
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virus-infected hNPs in vitro, we performed immunocyto-
chemistry with the following antibodies: anti-hNestin 
(human-specific Nestin, 1:200; Chemicon, Temecula, CA), 
anti-GFAP (glial fibrillary acidic protein, 1:1500; Dako, 
Carpinteria, CA), anti-hGFAP (human-specific GFAP, 1:500; 
Sternberger, Lutherville, MD), anti-Tuj1 (neuronal class 
β-Tubulin III, 1:500; Covance, Berkeley, CA), anti-NeuN 
(neuronal nuclear protein, 1:40; Chemicon), anti-CNPase 
(2'3'-cyclic nucleotide 3'-phosphodiesterase, 1:100; Chemi-
con), anti-O4 (oligodendrocyte marker O4, 1:200; Chemi-
con), anti-GFP (1:300; Invitrogen), anti-Chat (choline ace-
tyltransferase, 1:200; Chemicon), anti-PDGFR (platelet-de-
rived growth factor receptor, 1:100; Santa Cruz Biotechno-
logy, Inc., Santa Cruz, CA), FITC-conjugated anti-BrdU 
(1:20; Roche, Mannheim, Germany), biotin-conjugated 
anti-hHSP27 (human-specific heat shock protein 27, 1:40; 
Stressgen, Ann Arbor, MI), anti-EAAT1 (1:100; Santa Cruz 
Biotechnology), anti-EAAT2 (1:100; Santa Cruz Biotechno-
logy), and anti-GDNF (1:50; Santa Cruz Biotechnology). 
    After transplantation, immunohistochemical analysis of 
brain and spinal cord tissue of ALS mice model was 
performed. We first perfused the mice with chilled 1× PBS 
and 4% paraformaldehyde (PFA; Sigma) in 0.1M PIPES 
buffer, and then the brain and spinal cord were removed 
and post-fixed. These tissues were cut in 16-μm sections 
on cryostat and stained with the antibodies described 
above. The stained sections were mounted and examined 
by immunofluorescence microscopy (B×51; OLYMPUS, 
Tokyo, Japan).
Statistics
Because transgenic mice have different characters according 
to litter cage, data were analyzed primarily by unpaired 
t-test. Survival analysis was conducted by Kaplan-Meier 
method. All data are shown as mean ± standard error of 
the mean (SEM).
Supplemental data
Supplemental Data include a figure and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-41-7-05.pdf.
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